Company Performance - Teladoc's stock closed at $8.58, down 1.49%, underperforming the S&P 500 which lost 0.11% [1] - Over the past month, Teladoc shares gained 26.78%, significantly outperforming the Medical sector's gain of 1.66% and the S&P 500's gain of 5.17% [1] Earnings Expectations - The upcoming earnings report is expected to show an EPS of -$0.27, a 3.57% increase from the same quarter last year [2] - Revenue is projected at $621.69 million, down 3.23% from the previous year [2] Full Year Projections - For the full year, analysts expect earnings of -$1.2 per share and revenue of $2.52 billion, reflecting changes of +79.56% and -2.12% respectively from last year [3] - Recent revisions in analyst estimates are crucial as they indicate confidence in the company's performance and profit potential [3] Zacks Rank and Industry Position - The Zacks Rank system currently rates Teladoc as 3 (Hold), with a recent 6.59% decrease in the EPS estimate over the last 30 days [5] - The Medical Services industry, which includes Teladoc, has a Zacks Industry Rank of 68, placing it in the top 28% of over 250 industries [6]

February 2025 Disclaimer Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the future performance of 23andMe's businesses in consumer genetics and therapeutics and the growth and potential of its proprietary research platform. All statements, other than statements of historical fact, included or incorpor ...

Teladoc (TDOC) shares rallied 14.4% in the last trading session to close at $7.89. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 1.3% gain over the past four weeks.Teladoc witnessed a price rise after Citron Research highlighted strong growth prospects following the company’s Goldman Sachs presentation, where management revealed that embedding BetterHelp in employer health plans could drastically improve co ...

Company Performance - Teladoc's stock increased by 2.33% to $7.02, outperforming the S&P 500's daily gain of 0.94% [1] - Over the past month, Teladoc's stock has decreased by 8.78%, underperforming the Medical sector's gain of 4.95% and the S&P 500's gain of 1.67% [1] Upcoming Earnings - The upcoming earnings release is expected to show an EPS of -$0.24, which is a 14.29% increase compared to the same quarter last year [2] - Revenue is projected to be $621.69 million, reflecting a 3.23% decline from the equivalent quarter last year [2] Fiscal Year Projections - For the entire fiscal year, earnings are projected at -$1.17 per share, representing an 80.07% increase from the prior year [3] - Revenue for the fiscal year is estimated at $2.52 billion, indicating a 2.12% decrease from the previous year [3] Analyst Estimates - Recent modifications to analyst estimates for Teladoc reflect short-term business trends, with positive revisions indicating analyst optimism [4] - The Zacks Rank system, which incorporates estimate changes, currently ranks Teladoc at 3 (Hold) [6] Industry Context - The Medical Services industry, part of the Medical sector, holds a Zacks Industry Rank of 67, placing it in the top 28% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Company Overview - Teladoc's stock closed at $7.40, reflecting a +1.79% change from the previous day, outperforming the S&P 500's daily gain of 0.09% [1] - Over the past month, Teladoc's stock has increased by 2.25%, slightly above the Medical sector's gain of 2.17%, but below the S&P 500's gain of 7.21% [1] Earnings Forecast - The upcoming earnings release is anticipated, with an expected EPS of -$0.23, indicating a 17.86% growth compared to the same quarter last year [2] - Revenue is forecasted to be $621.92 million, representing a 3.19% decline from the corresponding quarter of the previous year [2] Full Year Projections - For the full year, earnings are projected at -$1.17 per share and revenue at $2.51 billion, showing changes of +80.07% and -2.15% respectively from the previous year [3] Analyst Forecast Revisions - Recent revisions to analyst forecasts for Teladoc are important, as they reflect changes in short-term business dynamics [4] - Positive revisions indicate analysts' confidence in the company's performance and profit potential [4] Zacks Rank System - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has a history of outperforming, with 1 stocks averaging a +25% annual gain since 1988 [6] - Over the last 30 days, the Zacks Consensus EPS estimate for Teladoc has increased by 8.56%, and the company currently holds a Zacks Rank of 3 (Hold) [6] Industry Context - The Medical Services industry, part of the Medical sector, has a Zacks Industry Rank of 68, placing it in the top 28% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Core Insights - Doximity (DOCS) experienced strong revenue growth in fiscal 2025, with total revenues for Q4 reaching $138.3 million, a 17% year-over-year increase driven by subscription revenues [1][6] - The demand for telehealth services is expected to continue rising into fiscal 2026, supported by a record number of unique active users and a significant increase in sales to top clients [1][6] - The company's strategic focus is shifting towards clinical AI products, which aligns with the growing demand for productivity-enhancing tools among physicians [2] Company Performance - Doximity's subscription revenue for Q4 was $131.9 million, also reflecting a 17% year-over-year growth [1][6] - Unique active prescribers exceeded 620,000 in Q4, indicating robust engagement with the platform [1] - Sales to the top 20 clients surged by 23% during fiscal 2025, suggesting strong future growth potential [1][6] Product and Service Demand - The newsfeed product saw a 30% year-over-year increase in articles accessed, contributing to record engagement levels [2] - AI tools, including Doximity GPT, were the fastest-growing segment, increasing over 5 times year-over-year [2] - The company is transitioning its focus from client portals to clinical AI products to address physician burnout and enhance monetization opportunities [2] Industry Context - Competitors like HealthEquity (HQY) and Teladoc Health (TDOC) are also experiencing growth, with HQY reporting a 15% increase in sales to $330.8 million in Q1 of fiscal 2026 [3] - Teladoc Health, despite a decline in operational revenues, reported better-than-expected results due to growth in international revenues and an expanding membership base [4] Valuation and Earnings Estimates - Doximity's shares have gained 0.2% year-to-date, contrasting with a 4.3% decline in the industry [5] - The company trades at a forward price-to-earnings ratio of 36.05, above the industry average but lower than its five-year median of 52.54 [8] - The Zacks Consensus Estimate for Doximity's 2025 earnings suggests a 2.8% increase from the previous year [9]

Core Insights - Hims & Hers Health Inc announced the acquisition of ZAVA, a European digital health platform, which impacted its stock performance in premarket trading [1] - Hims stock experienced volatility, trading as high as $67.35 but later declining by 2.5% to $55.37, while still showing a 128% year-to-date gain [2] - Doximity Inc saw a 3.9% increase in stock price to $53.50, with a recent upgrade from BTIG to "buy" from "hold," and a year-over-year increase of 93.6% [3] - Teladoc Health Inc's stock rose by 2.9% to $7.07, but it remains 22.2% lower year-to-date and far from its February 2021 highs of nearly $300 [4] - The options market shows a strong preference for call options, with a call/put volume ratio of 17.12, indicating a bullish sentiment among investors [5] Company Summaries - Hims & Hers Health Inc is focusing on expanding its digital health services through the acquisition of ZAVA, which may enhance its market position [1] - Doximity Inc is recovering from previous lows, with a significant year-over-year increase and a recent positive analyst rating, suggesting potential for further growth [3] - Teladoc Health Inc is struggling with a significant year-to-date deficit, indicating challenges in regaining its previous high market valuation [4] Market Trends - The telehealth sector is experiencing varied stock performances, with some companies like Hims and Doximity showing strong gains, while others like Teladoc are facing declines [2][4] - The options market reflects a bullish outlook for telehealth stocks, with a notable preference for call options over puts, suggesting investor confidence in future price increases [5]

Core Points - Health Net is responding to the State of Emergency declared by Gov. Newsom in San Joaquin County due to the Victoria Island Incident, prioritizing support for affected members and healthcare providers [1] Member Support Initiatives - Members can secure emergency medication supplies through two options during the State of Emergency [2] - Health Net offers 24/7 crisis support via Behavioral Health Services and telehealth services at no cost for members unable to reach their primary care provider [2][3] - Members can access local community resources by calling 2-1-1 or visiting 211.org [3] Healthcare Provider Support - Healthcare providers can contact Health Net for assistance during the emergency, with specific support measures in place for those in affected areas [3][4] - Health Net will suspend refill limitations for prescriptions at out-of-network pharmacies if the original pharmacy is closed [4] Additional Resources and Services - Health Net is providing ongoing support including mental health referrals, social services, financial assistance, and legal guidance [4] - The company will extend grace periods for notifications related to various healthcare services and waive prior authorization requirements while maintaining notification requirements [4] Company Overview - Health Net, a subsidiary of Centene Corporation, has been operating in California for over 45 years, serving more than three million members with a network of over 117,000 providers [6] - The company offers a range of health plans and services, including behavioral health and substance abuse programs, and employs over 5,700 people in California [6]

Trade Policy Impact - The United States has implemented new tariffs, with a 10% baseline tariff on most imports and up to 145% on Chinese goods, significantly affecting global trade dynamics [1] - The elimination of the "de minimis" exemption for shipments under $800 impacts low-cost Chinese e-commerce platforms like Temu and Shein [1] - China has responded by suspending exports of critical minerals, escalating the trade conflict and increasing uncertainty in global markets [1] Economic Consequences - Previous tariffs from 2018 to 2020 resulted in over $80 billion in additional costs for American businesses and consumers, raising concerns about price increases and margin compression across industries [2] - The reintroduction of tariffs in 2025 has raised alarms in the corporate sector, particularly regarding the implementation timeline and potential retaliatory measures from trade partners like China [2] Pharmaceutical Sector - The U.S. government is preparing to impose tariffs on select pharmaceutical imports from countries like China and India, raising concerns about increased costs and supply chain disruptions [3] - Pharmaceutical companies, reliant on international manufacturing, are particularly vulnerable to trade disruptions, leading to a cautious sentiment in the industry [3] Medical Device Sector - The medical device sector is identified as a strong investment opportunity, driven by technological advancements, demographic trends, and increasing demand for healthcare solutions [4] - The global medical devices market was valued at $518.46 billion in 2023 and is projected to grow to over $886.80 billion by 2032, with a CAGR of 6.3% [5] Investment Opportunities - Amid tariff uncertainties, investors are focusing on undervalued stocks with strong balance sheets and resilient performance, particularly in the medical device sector [6] - Promising undervalued stocks for 2025 include Cencora, Inc. (COR), Hims & Hers Health (HIMS), and Prestige Consumer (PBH) [6] Cencora, Inc. - Cencora is a major pharmaceutical services company with a diverse portfolio, including biologics and complex injectables [7] - The company has launched Accelerate Pharmacy Solutions to optimize operations for healthcare customers and has acquired Retina Consultants of America to enhance its specialty leadership [8] - Cencora's stock trades at a P/S ratio of 0.17, lower than the Medical Services market's 0.40, with an expected 11.6% growth in 2025 earnings [9] Hims & Hers Health - Hims & Hers Health offers subscription-based telehealth services and aims to simplify healthcare through a digital-first platform [10] - The company has a P/S ratio of 2.47, discounted compared to the industry's 4.03, with a projected 58% growth in 2025 earnings [11] Prestige Consumer - Prestige Consumer provides over-the-counter healthcare products and has a strong presence across various retail channels [12] - The gastrointestinal product category is a significant growth driver, representing nearly one-fifth of North American sales [13] - The stock trades at a P/S ratio of 3.43, lower than the industry's 5.32, with a recent earnings surprise of 5.17% [16]